Clinical review for general practice

Proton pump inhibitors are the most effective drugs for the treatment of acid-related diseases. In recent decades, the use of PPIs has increased exponentially. For a long time, PPIs were considered completely safe drugs for both short-term and long-term use. However, modern clinical guidelines note that when prescribing PPIs in large doses for a long period, the possibility of side effects should be taken into account. There are no reviews in the domestic literature on the safety of PPIs during long-term use. In this regard, a search was conducted in the PubMed and Scopus information databases for publications on the safety of PPI use, including sources up to November 15, 2023, which showed that long-term use of PPIs is associated with the possible development of numerous side effects. The first publications examined the likely side effects of long-term use of PPIs: the development of infections, increased risk of fractures and kidney pathology, and possible side effects: the risk of cancer and electrolyte disturbances. This review examines the possible cardiovascular risk of long-term PPI use and a number of rare side effects, many of which have been described in recent years. The key to mitigating side effects is judicious use of PPIs at the lowest effective dose and as quickly as possible. If there are clear indications for long-term PPI use, monitoring should be carried out to identify side effects.

Keywords: proton pump inhibitors, drug safety, side effects, cardiovascular risk, adverse cardiovascular events, myocardial infarction, stroke, dementia, erectile dysfunction, diabetes mellitus, bronchial asthma, chronic obstructive pulmonary disease.

1. Ивашкин В.Т., Маев И.В., Царьков П.В. и др. Диагностика и лечение язвенной болезни у взрослых. Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(1):49-70. DOI: 10.22416/1382-4376-2020-30-1-49-70 Ivashkin V.T., Maev I.V., Tsar’kov P.V. et al. Diagnosis and Treatment of Peptic Ulcer in Adults. Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):49-70. DOI: 10.22416/1382-4376-2020-30-1-49-70 (in Russian).

2. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97. DOI: 10.22416/1382-4376-2020-30-4-70-97 Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Refl ux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97. DOI: 10.22416/1382-4376-2020-30-4-70-97 (in Russian).

3. Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis. 2020;75:497–507. DOI: 10.1053/j.ajkd.2019.07.012

4. 2021 Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике. Российский кардиологический журнал. 2022;27(7):5155. DOI:10.15829/1560-4071-2022-5155 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Russian Journal of Cardiology. 2022;27(7):5155. DOI: 10.15829/1560-4071-2022-5155 (in Russian).

5. Трухан Д.И., Давыдов Е.Л., Шевченко Г.Ю. Контроль гликемии у коморбидных пациентов – важный компонент в профилактике прогрессирования сердечно-сосудистых заболеваний. Медицинский совет. 2023;17(16):60-7. DOI: 10.21518/ms2023-307 Trukhan D.I., Davidov E.L., Shevchenko G.Yu. Glycaemic control in comorbid patients: an important element of CVD progression prevention. Meditsinskiy Sovet. 2023;17(16):60-7. DOI: 10.21518/ms2023-307 (in Russian).

6. Трухан Д.И. Лекарственная безопасность: в фокусе долгосрочная терапия ингибиторами протонной помпы. Вероятные побочные эффекты. Клинический разбор в общей медицине. 2024;5(1).  Trukhan D.I. Drug safety: long-term therapy with proton pump inhibitors is in focus. Possible side effects. Clinical review for general practice. 2024;5(1) (in Russian).

7. Трухан Д.И. Лекарственная безопасность: в фокусе долгосрочная терапия ингибиторами протонной помпы. Возможные побочные эффекты. Клинический разбор в общей медицине. 2024;5(2).  Trukhan D.I. Drug safety: long-term therapy with proton pump inhibitors is in focus. Possible side effects. Clinical review for general practice. 2024;5(1) (in Russian).

8. Ariel H, Cooke JP. Cardiovascular risk of proton pump inhibitors. Methodist Debakey Cardiovasc J. 2019;15:214-19. DOI: 10.14797/mdcj-15-3-214

9. Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021;76(1):13-21. DOI: 10.1016/j.therap.2020.06.019

10. Rooney MR, Bell EJ, Alonso A et al. Proton Pump Inhibitor Use, Hypomagnesemia and Risk of Cardiovascular Diseases: The Atherosclerosis Risk in Communities (ARIC) Study. J Clin Gastroenterol. 2021;55 (8):677-83. DOI: 10.1097/MCG.0000000000001420

11. Sun S, Cui Z, Zhou M et al. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis. Neurogastroenterol Motil. 2017;29:e12926 DOI: 10.1111/nmo.12926

12. Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and proton pump inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: a systematic review and meta-analysis of recently published studies (2012-2016). BMC Cardiovasc Disord. 2017;17(1):3. DOI: 10.1186/s12872-016-0453-6

13. Batchelor R, Kumar R, Gilmartin-Thomas JFM et al. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48(8):780-96. DOI: 10.1111/apt.14955

14. Pang J, Wu Q, Zhang Z et al. Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2019;23:100317. DOI: 10.1016/j.ijcha.2018.12.016

15. Freedberg DE, Yang YX, Abrams JA. Proton pump inhibitors and myocardial infarction. Gastroenterology. 2015;149:830-3. DOI: 10.1053/j.gastro.2015.08.002

16. Qian Y, Jick S. Proton-pump inhibitor use and myocardial infarction: a nested case-control study in the UK Clinical Practice Research Datalink. Epidemiology. 2020;31:423-31. DOI: 10.1097/EDE. 0000000000001152

17. Tseng HJ, Cheng CM, Tsai SJ et al. Proton pump inhibitor exposure and acute myocardial infarction risk: a nested cohort study. Cardiovasc Toxicol. 2021;21:444-50. DOI: 10.1007/s12012-021-09637-2

18. Ghebremariam YT, LePendu P, Lee JC et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128:845-53. DOI: 10.1161/CIRCULATIONAHA.113.003602

19. Kang MK, Shin JH, Kim TJ et al. Use of proton pump inhibitor may be associated with progression of cerebral small vessel disease. PLoS One. 2022;17:e0279257. DOI: 10.1371/journal.pone.0279257

20. Sehested TSG, Gerds TA, Fosbøl EL et al. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction. J Intern Med. 2018;283:268-81. DOI: 10.1111/joim.12698

21. Wang YF, Chen YT, Luo JC et al. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. Am J Gastroenterol. 2017;112:1084-93. DOI: 10.1038/ajg.2017.101

22. Yang M, He Q, Gao F et al. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Med. 2021;19:316 DOI: 10.1186/s12916-021-02180-5

23. Li S, Liu F, Chen C et al. Real-world relationship between proton pump inhibitors and cerebro-cardiovascular outcomes independent of clopidogrel. Int Heart J. 2019;60:910-18 DOI: 10.1536/ihj.18-584

24. Farhat N, Fortin Y, Haddad N et al. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents. Crit Rev Toxicol. 2019;49:215-61. DOI: 10.1080/10408444.2019.1583167

25. Nolde M, Ahn N, Dreischulte TA et al. The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018). Aliment Pharmacol Ther. 2021;54:1033-40. DOI: 10.1111/apt.16565

26. Shang YS, Zhong PY, Ma Y et al. Efficacy and safety of proton pump inhibitors in patients with coronary artery diseases receiving oral antiplatelet agents and/or anticoagulants: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2022;80:1-12. DOI: 10.1097/FJC. 0000000000001284

27. Nolde M, Ahn N, Dreischulte T et al. Proton pump inhibitors and the risk of cardiovascular events and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2022;106:80-9. DOI: 10.1016/j.ejim.2022.09.021

28. Chui CSL, Cheung KS, Brown JP et al. Proton pump inhibitors and myocardial infarction: an application of active comparators in a self-controlled case series. Int J Epidemiol. 2022; 9(3):899-907. DOI: 10.1093/ije/dyac196

29. Ortiz-Guerrero G, Amador-Muñoz D, Calderón-Ospina CA et al. Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences. Neural Plast. 2018;2018:5257285. DOI: 10.1155/2018/5257285

30. Gomm W, von Holt K, Thomé F et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016;73(4):410-6. DOI: 10.1001/jamaneurol.2015.4791

31. Zhang Y, Liang M, Sun C et al. Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies. Eur J Clin Pharmacol. 2020;76(2):139-47. DOI: 10.1007/s00228-019-02753-7

32. Ahn N, Nolde M, Krause E et al. Do proton pump inhibitors increase the risk of dementia? A systematic review, meta-analysis and bias analysis. Br J Clin Pharmacol. 2023;89(2):602-16. DOI: 10.1111/bcp. 15583

33. Zhang P, Li Z, Chen P et al. Regular proton pump inhibitor use and incident dementia: population-based cohort study. BMC Med. 2022;20(1):271. DOI: 10.1186/s12916-022-02478-y

34. Pourhadi N, Janbek J, Jensen-Dahm C et al. Proton pump inhibitors and dementia: A nationwide population-based study. Alzheimers Dement. 2023; Oct 5. DOI: 10.1002/alz.13477

35. Caetano C, Veloso M, Borda S. Proton pump inhibitors and dementia: what association? Dement Neuropsychol. 2023 May 29;17:e20220048. DOI: 10.1590/1980-5764-DN-2022-0048.

36. Desai M, Nutalapati V, Srinivasan S et al. Proton pump inhibitors do not increase the risk of dementia: a systematic review and meta-analysis of prospective studies. Dis Esophagus 2020;33:doaa041. DOI: 10.1093/dote/doaa041

37. Khan MA, Yuan Y, Iqbal U et al. No association linking short-term proton pump inhibitor use to dementia: systematic review and meta-analysis of observational studies. Am J Gastroenterol 2020;115:671-8. DOI: 10.14309/ajg.0000000000000500

38. Hussain S, Singh A, Zameer S et al. No association between proton pump inhibitor use and risk of dementia: evidence from a meta-analysis. J Gastroenterol Hepatol. 2020;35:19-28. DOI: 10.1111/jgh.14789

39. Perry TW. Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report. J Med Case Rep. 2021;15(1):360. DOI: 10.1186/s13256-021-02981-5

40. Ashfaq M, Haroon MZ, Alkahraman YM. Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual disorders. Endocr Regul. 2022;56(2):134-47. DOI: 10.2478/enr-2022-0015

41. Kumar A, Kumar R, Flanagan J et al. Esomeprazole reduces sperm motility index by targeting the spermic cholinergic machinery: A mechanistic study for the association between use of proton pump inhibitors and reduced sperm motility index. Biochem Pharmacol. 2020;182:114212. DOI: 10.1016/j.bcp.2020.114212

42. Ashfaq M, Khan Q, Haroon MZ et al. Long-Term Proton Pump Inhibitor Therapy and its Effect on Endocrine Hormones in Selected Patient Population. Horm Metab Res. 2023;55(3):205-11. DOI: 10.1055/a-2009-9629

43. Yuan J, He O, Nguyen LH et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2020;Sep 28;gutjnl-2020-322557. DOI: 10.1136/gutjnl-2020-322557

44. Ciardullo S, Rea F, Savaré L et al. Prolonged Use of Proton Pump Inhibitors and Risk of Type 2 Diabetes: Results From a Large Population-Based Nested Case-Control Study. J Clin Endocrinol Metab. 2022;107(7):e2671-e2679. DOI: 10.1210/clinem/dgac231

45. Guo YR, Liu XM, Wang GX. Exposure to proton pump inhibitors and risk of diabetes: A systematic review and meta-analysis. World J Diabetes. 2023;14(2):120-9. DOI: 10.4239/wjd.v14.i2.120

46. Czarniak P, Ahmadizar F, Hughes J et al. Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study. Br J Clin Pharmacol. 2022;88(6):2718-26. DOI: 10.1111/bcp.15182

47. Wang WT, Li CY, Chang YT et al. Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study. Allergy Asthma Proc. 2023;44(5):345-53. DOI: 10.2500/ aap.2023.44.230035

48. Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children. JAMA Pediatr. 2021;175(4):394-403. DOI: 10.1001/jamapediatrics.2020.5710

49. Janetzki JL, Sykes MJ, Ward MB, Pratt NL. Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease – A sequence symmetry analysis approach. J Clin Pharm Ther. 2021;46(6):1687-94. DOI: 10.1111/jcpt.13520

50. Salloum A, Nasr D, Maalouf D. Dermatologic adverse reactions to proton-pump inhibitors: A synthetized review. J Cosmet Dermatol. 2021;20(4):1073-9. DOI: 10.1111/jocd.13763

51. Трухан Д.И. Синдром бабуина или симметричная интертригинальная и изгибная экзантема, связанная с лекарственными средствами. Обзор клинических случаев. Клинический разбор в общей медицине. 2023;4(5): 63-70. DOI: 10.47407/kr2023.4.5.00236.  Trukhan D.I. Baboon syndrome or symmetric intertriginal and flexible exanthemas associated with medicines. Review of clinical cases. Clinical review for general practice. 2023;4(5): 63-70. DOI: 10.47407/kr2023.4.5.00236 (in Russian).

52. Kardaun SH, Tupker RA. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) induced by omeprazole. Int J Dermatol. 2012;51(9):1134-7. DOI: 10.1111/j.1365-4632.2010.04689.x

53. Kothari R, Pal R, Bhatnagar A, Kishore K, Patil C. A rare case of symmetrical drug-related intertriginous and flexural exanthema due to pantoprazole. Int J Dermatol. 2022 Sep;61(9):e330-e331. DOI: 10.1111/ijd.16155

54. Spigariolo CB, Barei F, Maronese CA et al. Three cases of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by proton-pump inhibitors. Australas J Dermatol. 2022;63(4):509-12. DOI: 10.1111/ajd.13905

55. Pipaliya N, Solanke D, Rathi C et al. Esomeprazole induced galactorrhea: a novel side effect. Clin J Gastroenterol. 2016;9(1):13-6. DOI: 10.1007/s12328-015-0622-7

56. Tröger U, Reiche I, Jepsen MS et al. Esomeprazole-induced rhabdomyolysis in a patient with heart failure. Intensive Care Med. 2010;36(7):1278-9. DOI: 10.1007/s00134-010-1854-0

57. Jeon DH, Kim Y, Kim MJ et al. Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report. Medicine (Baltimore). 2016;95(29):e4313. DOI: 10.1097/MD.0000000000004313

58. Nishikawa J, Hosokawa A, Fuchino M et al. Rhabdomyolysis associated with long-term treatment of esomeprazole. Nihon Shokakibyo Gakkai Zasshi. 2018;115(3):299-304. DOI: 10.11405/nisshoshi.115.299

59. Dury S, Nardi J, Gozalo C et al. Agranulocytosis induced by proton pump inhibitors. J Clin Gastroenterol. 2012;46(10):859. DOI: 10.1097/MCG.0b013e318236f18a

60. Caboni S, Gunera-Saad N, Ktiouet-Abassi S et al. Esomeprazole-induced DRESS syndrome. Studies of cross-reactivity among proton-pump inhibitor drugs. Allergy. 2007;62(11):1342-3. DOI: 10.1111/j.1398-9995.2007.01428.x

61. Derlon V, Audibert G, Barbaud A, Mertes PM. DRESS in intensive care unit: a challenging diagnosis and treatment. Ann Fr Anesth Reanim. 2014;33(12):693-5. DOI: 10.1016/j.annfar.2014.08.007

62. Zaïem A, Charfi O, Badri T, Elaidli S. Fatal outcome of DRESS syndrome associated with esomeprazole. Indian J Dermatol Venereol Leprol. 2015;81(4):407-8. DOI: 10.4103/0378-6323.158636

63. Almebayadh M, Regnier-Rosencher E, Carlotti A et al.  Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors. Dermatology. 2013;226(2):119-23. DOI: 10.1159/ 000346694

64. Sandholdt LH, Laurinaviciene R, Bygum A. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2014;170(2):342-51. DOI: 10.1111/bjd.12699

65. Gliem N, Broekaert SMC, Seitz CS et al. Esomeprazol-induced cutaneous lupus erythematosus Z. Gastroenterol. 2017;55(9):861-5. DOI: 10.1055/s-0043-113833

66. Yibirin M, De Oliveira D, Valera R et al. Adverse effects associated with proton pump inhibitor use. Cureus. 2021;13:e12759. DOI: 10.7759/cureus.12759

67. Тарасова Л.В., Трухан Д.И. Лекарственная безопасность в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2013;(4):81-7. https://elibrary.ru/item.asp?id=21440231 Tarasova L.V., Trukhan D.I. Drug safety in gastroenterology. Experimental and clinical gastroenterology. 2013;(4):81-7. https://elibrary.ru/item. asp?id=21440231 (in Russian)

68. Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности. Клинический разбор в общей медицине. 2020; (2): 29-39. DOI: 10.47407/kr2020.1.2.00015 Truhan D.I. Racional‘naya farmakoterapiya v real‘noj klinicheskoj praktike skvoz‘ prizmu mul‘timorbidnosti i lekarstvennoj bezopasnosti. Clinical review for general practice. 2020; (2): 29-39. DOI: 10.47407/kr2020. 1.2.00015 (in Russian).

69. Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности. Справочник поликлинического врача. 2019;(2):10-8. https://www.elibrary.ru/item.asp?id=44162870 Trukhan D.I., Konshu N.V. Rational pharmacotherapy in the clinic of internal diseases through the prism of multimorbidity and drug safety. Handbook for Practitioners Doctors. 2019;(2):10-8 (in Russian).

70. Savarino V, Dulbecco P, de Bortoli N et al. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19-24. DOI: 10.1016/j.ejim.2016.10.007

71. Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;11:1123-34. DOI: 10.1080/17512433. 2018.1531703

72. Nguyen PV, Tamaz R. Inappropriate prescription of proton pump inhibitors in a community setting. Can J Hosp Pharm. 2018;71:267-71. https://pubmed.ncbi.nlm.nih.gov/30186000/

73. Sattayalertyanyong O, Thitilertdecha P, Auesomwang C. The inappropriate use of proton pump inhibitors during admission and after discharge: a prospective cross-sectional study. Int J Clin Pharm. 2020;42:174-83. DOI: 10.1007/s11096-019-00955-8

74. Agreus L, Borgquist L, Tsoposidis A et al. Significant over- and misuse of PPIs. Lakartidningen. 2021;118:20220. https://pubmed.ncbi. nlm.nih.gov/34216475/

75. Haastrup PF, Jarbøl DE, Thompson W et al. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol. 2021;8:e000563 DOI: 10.1136/bmjgast-2020-000563

76. Farrell B, Pottie K, Thompson Wet al. Deprescribing proton pump inhibitors: evidence-based clinical practice guideline. Can Fam Physician. 2017;63:354-64. https://pubmed.ncbi.nlm.nih.gov/28500192/

77. Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8:273-97 DOI: 10.1177/2042098617715381

78. Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162:1334-42. DOI: 10.1053/j.gastro.2021.12.247

79. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124:519-26. DOI: 10.1016/j.amjmed.2011.01.007

80. Markovits N, Loebstein R, Halkin H et al. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol. 2014;54(8):889-95. DOI: 10.1002/jcph.316

81. Xie Y, Bowe B, Li T et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91:1482-94. DOI: 10.1016/j.kint.2016.12.021

82. Klatte DCF, Gasparini A, Xu H et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153:702-10. DOI: 10.1053/j.gastro.2017.05.046

83. Wijarnpreecha K, Thongprayoon C, Chesdachai S et al. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis. Dig Dis Sci. 2017;62(10):2821-7. DOI: 10.1007/s10620-017-4725-5

84. Azab M, Doo L, Doo DH et al. Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis. Gut Liver. 2017;11(6):781-88. DOI: 10.5009/gnl16568

85. Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep. 2019;9:2282 DOI: 10.1038/s41598-019-39335-7

86. Park JH, Lee J, Yu SY et al. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease. BMC Geriatr. 2020;20(1):407. DOI: 10.1186/s12877-020-01794-3

87. Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020;55:453-61. DOI: 10.1007/s00535-019-01652-z

88. Zhang XY, He QS, Jing Z et al. Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank. Front Pharmacol. 2022;13:949699. DOI: 10.3389/fphar.2022.949699

89. Abrahami D, McDonald EG, Schnitzer ME et al. Proton pump inhibitors and risk of colorectal cancer. Gut. 2022;71:111-8. DOI: 10.1136/gutjnl-2021-325096

90. Kim HB, Kim JH, Wolf BJ. Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78(3):383-91. DOI: 10.1007/s00228-021-03255-1

91. Maret-Ouda J, Panula J, Santoni G et al. Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study. J Gastroenterol. 2023;58(8):734-40. DOI: 10.1007/s00535-023-02007-5